Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures.

Trial Profile

Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Fosphenytoin (Primary) ; Lacosamide (Primary)
  • Indications Seizures
  • Focus Therapeutic Use
  • Acronyms TRENdS
  • Most Recent Events

    • 07 May 2018 Status changed to discontinued, as per the results published in the Annals of Neurology
    • 07 May 2018 Primary endpoint (Percentage of subjects who experience no NCSs for 24 hours following treatment with LCM vs. fPHT, as measured by continuous) has been met, as per the results published in the Annals of Neurology.
    • 07 May 2018 Results published in the Annals of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top